Home › Drug Use and Addiction › NCT07768007

Real-time Opioid Study

Neurofeedback to Reduce Anhedonia and Improve Outcomes in Opioid Use Disorder: a Feasibility Study

Who can join

Ages 18 to 50 · All sexes

Inclusion Criteria:

* ≥3 months of methadone treatment for OUD
* Presence of anhedonia, as assessed via SHAPS
* Room for improvement in specific autobiographical memory recall, as assessed via AMT

Exclusion Criteria:

* Failure to pass an MRI screening
* Women who are pregnant
* Psychosis, as assessed via Yale PRIME Early Psychosis Screening Test
* Serious suicidal ideation
* Serious medical condition
* Legally blind

About the study

This feasibility study collects initial data on the use of an fMRI neurofeedback protocol for treating anhedonia in methadone-treated individuals with opioid use disorder (OUD). The intervention tested has previously been shown to reduce anhedonia in individuals with depression and this study is collecting first-in-human data in an OUD population. Investigators will assess tolerability of the intervention and collect preliminary data from 2-3 subjects monitoring changes in anhedonia, non-substance-related autobiographical memory recall, and meaning in life.

What is being tested

• real-time functional magnetic resonance imaging (rt-fMRI) neurofeedback (device)

Sponsor: Yale University · Participants: 3 · Started: Sep 8, 2026

Contact the study team

• Sarah Paprotna · Phone: +1 (203) 737-5994

Official record on ClinicalTrials.gov — NCT07768007

Locations in the U.S.

Conditions

• Drug Use and Addiction

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.